Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 723612, 8 pages
http://dx.doi.org/10.1155/2015/723612
Research Article

Retrospective Analysis of Bevacizumab in Combination with Fotemustine in Chinese Patients with Recurrent Glioblastoma Multiforme

1Department of Neurology, Xuzhou Center Hospital, Xuzhou 221009, China
2Department of Cancer, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
3Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
4Department of Neurology, Zhongshan Hospital, Xiamen University, Xiamen 361004, China

Received 8 November 2014; Revised 22 January 2015; Accepted 29 January 2015

Academic Editor: Eiichi Ishikawa

Copyright © 2015 Zhiguang Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. N. Louis, H. Ohgaki, O. D. Wiestler et al., “The 2007 WHO classification of tumours of the central nervous system,” Acta Neuropathologica, vol. 114, no. 2, pp. 97–109, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. Á. Oszvald, E. Güresir, M. Setzer et al., “Glioblastoma therapy in the elderly and the importance of the extent of resection regardless of age: clinical article,” Journal of Neurosurgery, vol. 116, no. 2, pp. 357–364, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Stupp, W. P. Mason, M. J. van den Bent et al., “Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma,” The New England Journal of Medicine, vol. 352, no. 10, pp. 987–996, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. R. Stupp, M. E. Hegi, W. P. Mason et al., “Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial,” The Lancet Oncology, vol. 10, no. 5, pp. 459–466, 2009. View at Publisher · View at Google Scholar
  5. H. S. Friedman, M. D. Prados, P. Y. Wen et al., “Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma,” Journal of Clinical Oncology, vol. 27, no. 28, pp. 4733–4740, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. T. N. Kreisl, L. Kim, K. Moore et al., “Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma,” Journal of Clinical Oncology, vol. 27, no. 5, pp. 740–745, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. M. C. Chamberlain and S. K. Johnston, “Salvage therapy with single agent bevacizumab for recurrent glioblastoma,” Journal of Neuro-Oncology, vol. 96, no. 2, pp. 259–269, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. A. de Rossi, L. Rossi, A. Laudisi et al., “Focus on fotemustine,” Journal of Experimental & Clinical Cancer Research, vol. 25, no. 4, pp. 461–468, 2006. View at Google Scholar · View at Scopus
  9. M. F. Avril, S. Aamdal, J. J. Grob et al., “Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study,” Journal of Clinical Oncology, vol. 22, no. 6, pp. 1118–1125, 2004. View at Google Scholar · View at Scopus
  10. V. Vaccaro, A. Fabi, A. Vidiri et al., “Activity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas,” BioMed Research International, vol. 2014, Article ID 351252, 7 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Yamamoto, S. Iwase, Y. Tsubota et al., “Bevacizumab in the treatment of five patients with breast cancer and brain metastases: Japan breast cancer research network-07 trial,” OncoTargets and Therapy, vol. 5, pp. 185–189, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. Arakawa, T. Mizowaki, D. Murata et al., “Retrospective analysis of bevacizumab in combination with ifosfamide, carboplatin, and etoposide in patients with second recurrence of glioblastoma,” Neurologia Medico-Chirurgica, vol. 53, no. 11, pp. 779–785, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Tabouret, M. Barrie, A. Thiebaut et al., “Limited impact of prognostic factors in patients with recurrent glioblastoma multiforme treated with a bevacizumab-based regimen,” Journal of Neuro-Oncology, vol. 114, no. 2, pp. 191–198, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. J. J. Vredenburgh, A. Desjardins, J. E. Herndon II et al., “Bevacizumab plus irinotecan in recurrent glioblastoma multiforme,” Journal of Clinical Oncology, vol. 25, no. 30, pp. 4722–4729, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Soffietti, E. Trevisan, L. Bertero et al., “Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology),” Journal of Neuro-Oncology, vol. 116, no. 3, pp. 533–541, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. H. S. Poulsen, K. Grunnet, M. Sorensen et al., “Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours,” Acta Oncologica, vol. 48, no. 1, pp. 52–58, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. D. A. Reardon, A. Desjardins, J. J. Vredenburgh et al., “Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a Phase II Study,” British Journal of Cancer, vol. 101, no. 12, pp. 1986–1994, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. J. J. C. Verhoeff, C. Lavini, M. E. van Linde et al., “Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma,” Annals of Oncology, vol. 21, no. 8, pp. 1723–1727, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. D. A. Reardon, A. Desjardins, K. B. Peters et al., “Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy,” Cancer, vol. 117, no. 23, pp. 5351–5358, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. B. Hasselbalch, U. Lassen, S. Hansen et al., “Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial,” Neuro-Oncology, vol. 12, no. 5, pp. 508–516, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Sathornsumetee, A. Desjardins, J. J. Vredenburgh et al., “Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma,” Neuro-Oncology, vol. 12, no. 12, pp. 1300–1310, 2010. View at Google Scholar · View at Scopus
  22. O. L. Chinot, W. Wick, W. Mason et al., “Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma,” The New England Journal of Medicine, vol. 370, no. 8, pp. 709–722, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Lacroix, D. Abi-Said, D. R. Fourney et al., “A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival,” Journal of Neurosurgery, vol. 95, no. 2, pp. 190–198, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Filippini, C. Falcone, A. Boiardi et al., “Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma,” Neuro-Oncology, vol. 10, no. 1, pp. 79–87, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. A. M. Stark, W. Stepper, and H. M. Mehdorn, “Outcome evaluation in glioblastoma patients using different ranking scores: KPS, GOS, mRS and MRC,” European Journal of Cancer Care, vol. 19, no. 1, pp. 39–44, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. P. Metellus, B. Coulibaly, I. Nanni et al., “Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort,” Cancer, vol. 115, no. 20, pp. 4783–4794, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Felsberg, N. Thon, S. Eigenbrod et al., “Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas,” International Journal of Cancer, vol. 129, no. 3, pp. 659–670, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. A. D. Norden, G. J. Lesser, J. Drappatz et al., “Phase 2 study of dose-intense temozolomide in recurrent glioblastoma,” Neuro-Oncology, vol. 15, no. 7, pp. 930–935, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. A. A. Brandes, A. Tosoni, G. Cavallo et al., “Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO),” British Journal of Cancer, vol. 95, no. 9, pp. 1155–1160, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Wick, J. Felsberg, J. P. Steinbach et al., “Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma,” Journal of Clinical Oncology, vol. 25, no. 22, pp. 3357–3361, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Sadones, A. Michotte, P. Veld et al., “MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma,” European Journal of Cancer, vol. 45, no. 1, pp. 146–153, 2009. View at Google Scholar · View at Scopus
  32. K. Zhang, X.-Q. Wang, B. Zhou, and L. Zhang, “The prognostic value of MGMT promoter methylation in Glioblastoma multiforme: a meta-analysis,” Familial Cancer, vol. 12, no. 3, pp. 449–458, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. S. L. Hervey-Jumper and M. S. Berger, “Reoperation for recurrent high-grade glioma: a current perspective of the literature,” Neurosurgery, vol. 75, no. 5, pp. 491–499, 2014. View at Publisher · View at Google Scholar
  34. A. Lai, A. Tran, P. L. Nghiemphu et al., “Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme,” Journal of Clinical Oncology, vol. 29, no. 2, pp. 142–148, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. N. Ahmadloo, A.-A. Kani, M. Mohammadianpanah et al., “Treatment outcome and prognostic factors of adult glioblastoma multiforme,” Journal of the Egyptian National Cancer Institute, vol. 25, no. 1, pp. 21–30, 2013. View at Publisher · View at Google Scholar · View at Scopus